期刊： HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022; 21 (6)
Background: Current surveillance strategies for hepatocellular carcinoma (HCC) among patients with nonalcoholic fatty liver disease (NAFLD) are insuff......
期刊： HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022; 21 (6)
Background: The shortage of donor liver restricts liver transplantation (LT). Nowadays, donor liver with ABO blood group incompatibility between donor......
期刊： HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022; 21 (1)
Pancreatic ductal adenocarcinoma (PDAC) is a common cause of cancer-related death, and most patients are with advanced disease when diagnosed. At pres......
期刊： HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022; 21 (3)
Background: Abdominal pain is often observed after endoscopic retrograde cholangiopancreatography (ERCP). Few studies have focused on the risk factors......
期刊： HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022; 21 (5)
Background: Fuzheng Huayu tablet is a traditional Chinese medicine (TCM) used for the treatment of liver fibrosis and cirrhosis. However, whether the ......
期刊： HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022; 21 (3)
Background: Inflammation is often related to cancer, and several inflammatory scores have been established to predict the prognosis of various types o......
期刊： HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022; 21 (4)
Background: Transcription factor 3 (TCF3) plays pivotal roles in embryonic development, stem cell maintenance and carcinogenesis. However, its role in......
期刊： HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022; 21 (5)
Background: The mortalities of hepatobiliary malignancies are high. With the failure of conventional chemotherapy and unsatisfactory outcome of molecu......
